20th week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200147103 | Compositions and Methods for Muscle Regeneration Using Prostaglandin E2 - Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition. | 2020-05-14 |
20200147104 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS - According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 2020-05-14 |
20200147105 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN - A method for contraception includes administering to a female daily, in a fourphasic dosing regimen during a time period of 24 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1125 mcg, in the third phase is 1250 mcg, and in the fourth phase is 1375 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 22.5 mcg, in the third phase is 25 mcg, and in the fourth phase is 27.5 mcg, and wherein the fourphasic dosing regimen is followed by 4 days without norethindrone acetate and EE administration. | 2020-05-14 |
20200147106 | COMPOSITIONS COMPRISING DEXAMETHASONE - A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof. | 2020-05-14 |
20200147107 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS - Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors. The GRM may be, e.g., mifepristone; the CYP3A inhibitors or steroidogenesis inhibitors (collectively “inhibitors”) may be, e.g., ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions; concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to the inhibitors and/or the other drugs. Applicant has surprisingly found that GRMs may be administered to subjects receiving inhibitors without increasing the risk of adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole or itraconazole, providing safe concomitant administration of the GRM and ketoconazole or itraconazole. In embodiments, the GRM dose may be reduced during concomitant administration of the GRM with inhibitors. | 2020-05-14 |
20200147108 | METHODS OF USING OBETICHOLIC ACID - The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis. | 2020-05-14 |
20200147109 | Spironolactone Aqueous Compositions - Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use. | 2020-05-14 |
20200147110 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS - The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual. | 2020-05-14 |
20200147111 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF - Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided. | 2020-05-14 |
20200147112 | DIET THERAPY OF INTRACTABLE CANCER AND MEDICAL DIET SUITABLE THEREFOR - An object of the present invention is to provide a diet therapy for suppressing tumor growth of refractory cancer, for treating refractory cancer, or for enhancing the effect of another cancer treatment. The present invention provides a saccharide restricted high fat composition for use in suppressing tumor growth of refractory cancer, treating refractory cancer and/or enhancing the effect of another cancer treatment. The composition of the present invention can comprise about 55% by mass or more of fat based on the total solid content contained in the composition. The composition of the present invention can also comprise about 0% by mass to about 15% by mass of saccharide based on the total solid content contained in the composition. The composition of the present invention can also comprise a medium chain fatty acid oil as fat. | 2020-05-14 |
20200147113 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MUTANT KCNJ5 - The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder. | 2020-05-14 |
20200147114 | COMPOSITION AND METHOD FOR TREATING ACUTE RESPIRATORY TRACT INFECTIONS - A composition consists of an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”), an effective amount of a synthetic neutral non-fucosylated HMO, and one or more excipients acceptable for enteral administration to a non-infant human. In some embodiments, the synthetic neutral fucosylated HMO is 2′-fucosyllactose and the synthetic neutral non-fucosylated HMO is selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”). In certain embodiments, the mass ratio of 2′-FL to the selected LNnT or LNT is about 1.5 to about 4.5. In one embodiment, the synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). In certain embodiments, the one or more excipients acceptable for enteral administration to a human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. In various embodiments, the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet. | 2020-05-14 |
20200147115 | USE OF ICARITIN IN PREPARING MEDICAMENT FOR PREVENTING OR TREATING HEMATOCYTOPENIA - The present application relates to a method of icaritin in preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia. | 2020-05-14 |
20200147116 | Use of Paeoniflorin-6'-O-benzenesulfonate in treatment of Sjogren's syndrome - The invention discloses the use of paeoniflorin-6′-O-benzenesulfonate of formula I in treatment of Sjögren's syndrome. Paeoniflorin-6′-O-benzenesulfonate of the invention, which has definitely curative effect, is characterized superiorly in that, it could be taken clinically for a long time with small dosage, mild adverse reaction and good patient compliance. The molecular formula of paeoniflorin-6′-O-benzenesulfonate is C | 2020-05-14 |
20200147117 | COMBINATION CANCER THERAPY - The present invention relates to combination therapies of a cytarabine conjugate and one or more anti-neoplastic agents for inhibiting cancer cell growth. In particular, the present invention relates to a conjugate of cytarabine and aspartic acid (BST-236) in combination with one or more additional anti-neoplastic agents for use in the treatment of hematological cancers. | 2020-05-14 |
20200147118 | COMPOSITIONS AND METHODS FOR DETECTION, RISK ASSESSMENT AND TREATMENT OF DIABETES, OBESITY, AND INFLAMMATION - Provided are compounds and compositions associated with obesity, diabetes and inflammation and methods of treating the same. | 2020-05-14 |
20200147119 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA - Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. | 2020-05-14 |
20200147120 | FUNCTION INHIBITOR OF SWI/SNF COMPLEXES - The present invention provides an anticancer agent based on a novel mechanism. Specifically, the present invention relates to an inhibitor that inhibits gene expression regulation by SWI/SNF complex-dependent NF-κB or a corepressor complex that participate in chromatin remodeling. More specifically, the present invention provides an inhibitor that reduces the interaction (such as binding and transcription regulation) of endogenous SWI/SNF complexes with NF-κB or a corepressor complex, or an inhibitor that inhibits the adapter function of d4 family proteins. The inhibitor of the present invention can be utilized in the treatment of cancers involving SWI/SNF complexes (such as SWI/SNF-mediated cancers). | 2020-05-14 |
20200147121 | MICELLIC ASSEMBLIES - Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles. | 2020-05-14 |
20200147122 | Nucleoporins as Drug Targets for Anti-Proliferative Therapeutics - Disclosed herein are methods of inhibiting nuclear pore complex assembly and inducing nuclear pore complex disassembly. Methods to screen for agents that inhibit nuclear pore assembly or induce nuclear pore complex disassembly are also disclosed. | 2020-05-14 |
20200147123 | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION - The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection. | 2020-05-14 |
20200147124 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS - Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound. | 2020-05-14 |
20200147125 | DETECTION OF HIGH RISK ARTERIAL THROMBOEMBOLIC DISEASES BY MARKERS OF COAGULATION AND HEMOSTATIC ACTIVATION - Disclosed herein is a method for identifying patients with cryptogenic stroke or embolic stroke of undetermined source (ESUS) who are at risk for having occult atrial fibrillation, underlying malignancy, and/or recurrent arterial thromboembolic events. Also disclosed is a method for determining who among these patients will benefit from anticoagulants. Also disclosed herein is a method to predict whether the anticoagulant is sufficiently effective to reduce the activated coagulation system in a patient. Also disclosed wherein is a method for identifying patients with cardiovascular and cerebrovascular arterial diseases who have occult atrial fibrillation, underlying but unrecognized malignancy, and/or are at high risk of recurrent arterial thromboembolic events. | 2020-05-14 |
20200147126 | PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID - Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles. | 2020-05-14 |
20200147127 | NO containing compositions - Disclosed are metal organic framework materials (MOFs), comprising an extra-framework NO releasing compound within the internal pores and/or channels of the MOF, the NO-releasing compounds and their preparation and uses. The MOFs and NO-releasing compounds are capable of releasing NO on application of an external stimulus and may provide materials with multiple modes of antibacterial and/or drug action. | 2020-05-14 |
20200147128 | USE OF LITHIUM ASCORBATE TO PREVENT AND TREAT ALCOHOLISM AND ALCOHOL INTOXICATION - The invention relates to medicine, particularly to the chemical and pharmaceutical industry and more particularly to the use of lithium ascorbate, in a dose of at least 5 mg/kg, as an agent for preventing and treating alcoholism and alcohol intoxication, and also providing protection of brain neurons and reducing demyelinating complications. The invention makes it possible to broaden the range of agents for this purpose. | 2020-05-14 |
20200147129 | Method, Target and Application for NO Accumulation to Decrease Pseudomonas Aeruginosa Invasiveness - Provided are a method, target and application for NO accumulation to decrease invasiveness of | 2020-05-14 |
20200147130 | FOOD SUPPLEMENTS FOR USE IN THE PROPHYLAXIS AND TREATMENT OF MIGRAINE - Association of dry extract of feverfew, dry extract of willow and magnesium for use as an adjuvant in the prophylaxis and treatment of migraine and related oral compositions, in particular as a food supplement. | 2020-05-14 |
20200147131 | METHODS OF TREATING BASAL CELL CARCINOMA AND GLIOBLASTOMA - Provided herein are methods of treating basal cell carcinoma or glioblastoma by administering coal tar or a coal tar product to a patient with basal cell carcinoma or glioblastoma. The coal tar or coal tar product may be administered as a standalone therapy or in combination with other treatments for basal cell carcinoma or glioblastoma. | 2020-05-14 |
20200147132 | MATURATION OF DENDRITIC CELLS - The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention. | 2020-05-14 |
20200147133 | Combination Therapy of Acellular Pro-Tolerogenic and Pro-Inflammatory Preparations for Modulating the Immune System - This disclosure relates to acellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one acellular pro-tolerogenic preparation and at least one acellular pro-inflammatory preparation are administered sequentially. | 2020-05-14 |
20200147134 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES - An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed. | 2020-05-14 |
20200147135 | COMPOSITIONS AND METHODS FOR AN IMPROVED ANTITUMOR IMMUNE RESPONSE - The present disclosure provides compositions and methods for improving an antitumor response against non-inflamed solid tumors. Methods of this disclosure include use of an eIF4A inhibitor to promote infiltration of antitumor lymphocytes into a non inflamed solid tumor. Methods of treating cancer associated with a non-inflamed solid tumor are also provided. | 2020-05-14 |
20200147136 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY - Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods. | 2020-05-14 |
20200147137 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - Disclosed herein are transmembrane proteins comprising at least two chains, each chain comprising an endodomain, a transmembrane domain, and an ectodomain; wherein the ectodomains of the at least two chains of the transmembrane protein interact together to bind to a drug or soluble protein; wherein the endodomains of the at least two chains of the transmembrane protein together comprise a structure functionally similar to that of an IL-2 receptor endodomain, an IL-7 receptor endodomain, or an IL-15 receptor endodomain; and wherein binding of the drug or soluble protein to the ectodomain activates IL-2, IL-7, or IL-15 signaling in CAR-bearing immune effector cells. | 2020-05-14 |
20200147138 | TREATMENT METHOD FOR KIDNEY TRANSPLANT REJECTION - Disclosed is a method for treating or preventing kidney transplantation rejection in a patient by administering to the patient autologous, ex vivo-modified and expanded CD4 | 2020-05-14 |
20200147139 | COMPOSITIONS CONTAINING A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER T CELLS AND METHODS FOR MAKING SAME - The present disclosure describes a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a cell product comprising an expanded and enriched population of superactivated cytokine killer T cells, and methods for manufacturing the cell product. | 2020-05-14 |
20200147140 | INTRAVENOUS ADMINISTRATION OF SUPRAPHYSIOLOGIC PLATELET RICH PLASMA FOR NEUROLOGICAL DISORDERS - This invention relates in general to the field of cell-therapy treatments and more particularly, but not by way of limitation, to systems and methods for administering personalized cell-therapy treatments intravenously. In various embodiments, the system may calculate an aspiration volume needed for centrifugation to achieve a concentrated target threshold dose of 2×10 | 2020-05-14 |
20200147141 | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG ACTING GLATIRAMER AND ADIPOSE-DERIVED STEM CELLS - Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis. | 2020-05-14 |
20200147142 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS - The invention encompasses compositions and method of treating a vascular disease such as peripheral artery disease, The methods involve—administering to a patient in need thereof, an effective amount of a composition comprising a population of cells such as mesenchymal stem cells (MSCs) and a non-muscle myosin 0 antagonist such as blebbistatin. Non-muscle myosin II antagonists are disclosed to surprisingly and dramatically accelerate MSC-triggered regeneration of damaged tissues arid unexpectedly and drastically reduce severe complications of stem cell treatment. | 2020-05-14 |
20200147143 | HUMAN ADULT HEPATOCYTE REPROGRAMMING MEDIUM COMPOSITION - The present invention relates to a human adult hepatocyte reprogramming medium composition and provides a method for inducing hepatic progenitor cells from human adult hepatocytes by means of a combination of chemicals. | 2020-05-14 |
20200147144 | METHODS OF TREATING JOINT DISEASE, DISORDERS AND CONDITIONS WITH TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES - Methods for treating joint diseases, disorders, and conditions, such as osteoarthritis, with a composition containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are provided. The composition can contain TIMPs as part of amniotic fluid, or the TIMPs can be isolated from another source or recombinantly produced. The methods are particularly useful for treating osteoarthritis associated with degradation of articular cartilage by proteases. Also provided are methods of lubricating a joint, such as an osteoarthritic joint. | 2020-05-14 |
20200147145 | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury - The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light. | 2020-05-14 |
20200147146 | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION - Provided is a pharmaceutical composition including a supernatant of a culture medium that has been used for maintenance culture of stem cells in an undifferentiated state. The stem cells for the pharmaceutical composition may be pluripotent stem cells. | 2020-05-14 |
20200147147 | MICRON FISH OIL COMPOSITION, AND PREPARATION PROCESS AND USES THEREOF - The present disclosure provides a micron fish oil composition and a method for preparing the micron fish oil composition. The method includes mixing a composite plant colloid with a fish oil and subjecting to an emulsification treatment to obtain an emulsion; and homogenizing the emulsion at a pressure of 300 bar to 350 bar to obtain the micron fish oil composition. The present disclosure also provides a method for enhancing bioabsorbability and bioavailability in a subject, including administering to the subject in need thereof a food product including an effective amount of the micron fish oil composition. | 2020-05-14 |
20200147148 | LIVE ATTENUATED PARASITIC VACCINE - Disclosed herein is an avirulent live vaccine that involves a recombinant protozoan from the order Trypanosomatida having a knocked out or silenced cyclophilin gene, wherein the cyclophilin gene comprises | 2020-05-14 |
20200147149 | COMPOSITIONS AND METHODS FOR THE MODULATION OF GUT SENSORY CELLS - The present disclosure relates to compositions and methods for modulating a transsynaptic signal through a neuroepithelial circuit between a gut sensory cell and the brain, as well as methods that involve modulating a transsynaptic signal through a neuroepithelial circuit between a gut sensory cell and the brain. | 2020-05-14 |
20200147150 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing brain injury. | 2020-05-14 |
20200147151 | COMPOSITIONS AND METHODS FOR FECAL MICROBIOTA TRANSPLANTATION - The present disclosure provides human fecal microbiota compositions, including fresh, frozen, and lyophilized compositions, for the treatment of disorders associated with dysfunctional microbiota, such as recurrent | 2020-05-14 |
20200147152 | PROBIOTIC OR PREBIOTIC, METHOD FOR PRODUCING SAME, MICROBIAL PREPARATION, HEALTH FOOD, AND MEDICINE - The diatheses of animals vary depending on genetic backgrounds of the animals, and the microbial structure of an enterobacterial flora inherent in a host and the behavior of the concentration of a biological molecule sometimes vary depending on the diathesis of the host. In this case, it is needed to administer a proper probiotic. | 2020-05-14 |
20200147153 | COMPOSITIONS COMPRISING BACTERIAL STRAIN - The invention provides compositions comprising bacterial strains for treating and preventing cancer. | 2020-05-14 |
20200147154 | SYNBIOTIC COMPOSITION FOR PREVENTING DISORDERS - The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life. | 2020-05-14 |
20200147155 | METHODS AND COMPOSITIONS TO MODULATE ANTIBIOTIC RESISTANCE AND GASTROINTESTINAL MICROBIOTA - Disclosed herein are methods and compositions related to probiotic formulas. These formulas comprise the bacterial strain | 2020-05-14 |
20200147156 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF - The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. | 2020-05-14 |
20200147157 | Composition Comprising Sargassum Horneri Extract For Alleviating Lung Injury Or Respiratory Disease - Disclosed is a composition comprising a | 2020-05-14 |
20200147158 | SANGHUANGPORUS SANGHUANG STRAINS AND THEIR PRODUCTS, EXTRACTS AND APPLICATIONS - The present invention relates to the preparation of a liquid fermentate of | 2020-05-14 |
20200147159 | BITTER GANODERMA LUCIDUM SPORE POWDER AND PREPARATION METHOD THEREOF - Disclosed is a method for preparing bitter | 2020-05-14 |
20200147160 | AGENT FOR SUPPRESSING CARBOHYDRATE BREAKDOWN AND ABSORPTION - The problem to be solved is to suppress an elevation of blood glucose level by suppressing decomposition and absorption of a carbohydrate in the body; and further prevent or improve diabetes and obesity derived from hyperglycemic symptoms and chronic hyperglycemia, for a long time. To attain the object, an agent for suppressing α-glucosidase activity and an agent for suppressing glucose absorption containing an amber extract as an active ingredient were invented. | 2020-05-14 |
20200147161 | HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF - Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine. | 2020-05-14 |
20200147162 | COMPOSITION FOR THE PREVENTION AND/OR IMPROVEMENT OF DRY EYE SYNDROME, DRYNESS OF THE EYE, AND STIFF NECK AND SHOULDER - A composition for the prevention and/or improvement of dry eye syndrome, dryness of eye and/or stiff neck and shoulder, which contains bilberry fruit extract and is effective with less intake. As one aspect of the present invention, the composition for the prevention or improvement of dry eye syndrome or dryness of eye contains a freeze-dried bilberry fruit extract. As another aspect of the present invention, the composition for the prevention or improvement of stiff neck and shoulder contains a freeze-dried bilberry fruit extract. As another aspect of the present invention, a composition for the prevention or improvement of dry eye syndrome, dryness of eye, and stiff neck and shoulder, contains a freeze-dried bilberry fruit extract. | 2020-05-14 |
20200147163 | PHARMACEUTICAL COMPOSITION COMPRISING REFINED INDIGO NATURALIS EXTRACTS AND THE USE THEREOF - A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition. | 2020-05-14 |
20200147165 | COMPOSITION AND METHOD FOR PREPARING PAIN RELIEVING DRUG - The present invention discloses a composition for preparing a pain relieving drug, which includes poplar bark, | 2020-05-14 |
20200147166 | HEALTH SUPPLEMENT FOOD FOR PROMOTION OF HAIR GROWTH, MITIGATION AND ALLEVIATION OF HAIR LOSS, REGULATION OF BLOOD GLUCOSE, AND ALLEVIATION AND RELIEF OF GASTRIC DISORDER SYMPTOMS - A method for alleviating hair loss includes using a health supplement food prepared by mixing dried powders that include 5 to 15% by weight of black beans, 5 to 15% by weight of black sesame seeds, 5 to 15% by weight of corn, 5 to 15% by weight of adlay, 5 to 15% by weight of | 2020-05-14 |
20200147167 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS - The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor. | 2020-05-14 |
20200147168 | DOSAGE OF A GLUTEN PEPTIDE COMPOSITION - Provided herein are methods and compositions for treating subjects with Celiac disease. | 2020-05-14 |
20200147169 | COMPOSITION COMPRISING A HIGH CONCENTRATION OF ITURIN LIPOPEPTIDES - The disclosure relates to compositions having a high concentration of iturinic lipopeptides. In particular, the compositions have an iturinic lipopeptide concentration of between 20 and 150 g/l; they are stable and homogeneous as a result of the presence of surfactants. | 2020-05-14 |
20200147170 | OPHTHALMIC COMPOSITIONS OF CYCLOSPORINE - The present invention relates to the ophthalmic composition comprising from about 0.03% to about 2% by weight of cyclosporine, from about 0.05% to about 5% by weight of tamarind seed polysaccharide and a pharmaceutically acceptable carrier. Further the invention relates to the process for preparation of ophthalmic compositions and its use for the treatment of dry eye. | 2020-05-14 |
20200147171 | COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS - The present invention relates to compositions and methods for modulating immune responses using at least one CRACC composition comprising an adenoviral vector comprising at least one CRACC fusion. Such CRACC compositions may be combined with a number of other therapeutic agents which target modulating immune responses, as well as, treatments that include immune events. | 2020-05-14 |
20200147172 | USE OF CREG IN TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES - The present invention relates to a use of cellular repressor of E1A-stimulated genes (CREG) protein, and in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The present invention also relates to a use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The invention also relates to a corresponding kit, such as a kit used for the predication and/or evaluation of therapeutic effect and prognosis of a fatty liver disease and type 2 diabetes. | 2020-05-14 |
20200147173 | BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE - Preventing or reducing the symptoms of lactose intolerance in an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. The effect is both acute (post-exposure to the composition) and ongoing (future exposure to lactose). | 2020-05-14 |
20200147174 | METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH - The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages. | 2020-05-14 |
20200147175 | METHOD FOR TREATING ANTI-HER2 THERAPY-RESISTANT MUC4+ HER2+ CANCER - A method for treating a patient suffering from an anti-HER2-resistant, MUC4+ HER2+ cancer is disclosed. For example, the method can be used to treat trastuzumab-resistant HER2+ breast cancer. In some embodiments, the method includes: (i) determining mucin-4 (MUC4) expression in cells of the patient; and (ii) if the MUC4 expression is greater than a predetermined-threshold, administering to the patient a therapeutically effective amount of a selective inhibitor of soluble tumor necrosis factor in combination with an anti-HER2 therapeutic agent, whereby said patient is treated. | 2020-05-14 |
20200147176 | Therapeutic RNA - This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers. | 2020-05-14 |
20200147177 | INTERLEUKIN 12 (IL12) OR DERIVATIVE THEREOF FOR USE IN THE TREATMENT OF SECONDARY DISEASE - The invention relates to Interleukin 12 (IL12) or derivative thereof for use in the treatment of secondary infection. The present invention also relates to pharmaceutical composition comprising Interleukin 12 (IL12) or derivative thereof for use in the treatment of secondary infection. The present invention finds application in the therapeutic and diagnostic medical technical fields. | 2020-05-14 |
20200147178 | COMPOSITIONS COMPRISING AN INTERLEUKIN CONSTRUCT - The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation. | 2020-05-14 |
20200147179 | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION - The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor. | 2020-05-14 |
20200147180 | METHOD FOR TREATING HYPERGLYCEMIA WITH GLP-1 - A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system. | 2020-05-14 |
20200147181 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 2020-05-14 |
20200147182 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 2020-05-14 |
20200147183 | CYCLIC ACETYLCHOLINESTERASE C-TERMINAL PEPTIDE IN THE TREATMENT OR PREVENTION OF CANCER OR METASTASIS - The invention relates to cyclic polypeptides derived from the C-terminus of acetylcholinesterase for use in treating or preventing cancer or metastatic disease. | 2020-05-14 |
20200147184 | METHODS FOR INTRODUCING MANNOSE 6-PHOSPHATE AND OTHER OLIGOSACCHARIDES ONTO GLYCOPROTEINS AND ITS APPLICATION THEREOF - Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications. | 2020-05-14 |
20200147185 | AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I - A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene and two or more immunosuppressants is provided herein. Also provided are methods useful for treating hIDUA deficiency (MPSI) and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes. | 2020-05-14 |
20200147186 | METHOD OF TREATING HEEL PAIN - A method treats heel pain related to a compression of the medial/plantar nerve complex of the heel between the Quadratus Plantae and/or the Abductor Hallucis muscles. The method includes injecting a botulinum toxin into the insertional plantar fascia area of each of the Abductor Hallucis and Quadratus Plantae muscles in a foot of a patient having the heel pain. | 2020-05-14 |
20200147187 | COMPOSITIONS AND METHODS FOR TREATING NEONATAL BILIARY ATRESIA - Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder may include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor. | 2020-05-14 |
20200147188 | THERAPEUTIC COMPOSITION CONTAINING ANTITHROMBIN GAMMA - A therapeutic composition including antithrombin gamma for diffuse intravascular coagulation or disseminated intravascular coagulation involving a decrease of antithrombin, or for thrombophilia due to congenital antithrombin deficiency and a method of using the composition are disclosed. | 2020-05-14 |
20200147189 | IDENTIFICATION OF MUTATIONS IN HERPES SIMPLEX VIRUS ENVELOPE GLYCOPROTEINS THAT ENABLE OR ENHANCE VECTOR RETARGETING TO NOVEL NON-HSV RECEPTORS - In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD. | 2020-05-14 |
20200147190 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-05-14 |
20200147191 | CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER - Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer. | 2020-05-14 |
20200147192 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-05-14 |
20200147193 | COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS - In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus. | 2020-05-14 |
20200147194 | PEPTIDE VACCINE AND PEPTIDE VACCINE COMPOSITION FOR CRANIAL NERVE DISEASE - A peptide vaccine for cranial nerve disease, containing a peptide that induces cytotoxic T-cells (CTLs) against Vascular Endothelial Growth Factor Receptor (VEGFR)-1-expressing cells, or a peptide that induces CTLs against VEGFR-2-expressing cells. | 2020-05-14 |
20200147195 | DTERT VACCINES AND METHODS OF TREATMENT USING THE SAME - Disclosed herein are compositions and methods for treating and/or preventing cancer in dogs, and in particular, vaccines that treat and provide protection against tumor growth. | 2020-05-14 |
20200147196 | NYVAC-BASED PLASMODIUM MALARIA VACCINE - The disclosure generally provides a WRrNYVAC comprising multiple antigens from different stages of a malaria parasite ( | 2020-05-14 |
20200147198 | Novel Multivalent Polysaccharide-Protein Conjugate Vaccine Composition and Formulation Thereof - Novel multivalent polysaccharide-protein conjugate vaccine formulation. The formulation is liquid or lyophilized or a Liquid-Lyo combination pentavalent formulation of | 2020-05-14 |
20200147199 | COMPOSITIONS AND METHODS RELATED TO HUMAN NEUTRALIZING ANTIBODIES TO ZIKA AND DENGUE 1 VIRUS - Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1. | 2020-05-14 |
20200147200 | RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF - The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting Marek's disease in combination with at least a second disease in poultry. | 2020-05-14 |
20200147201 | DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES - Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. | 2020-05-14 |
20200147202 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE - The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae. | 2020-05-14 |
20200147204 | MODIFIED VIRUSES - This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided. | 2020-05-14 |
20200147205 | POLYPEPTIDE CARRIER FOR PRESENTING TARGET POLYPEPTIDE AND USES THEREOF - The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV. | 2020-05-14 |